
Press Release

23 November 2020

Immunicum AB (publ) Announces Upcoming Investor Conferences in November and December

Immunicum AB (publ; IMMU.ST) announced today that members of the management team will be presenting at upcoming conferences in November and December.

Erik Penser Bank Bolagsdagen

Date: November 25, 2020
Presentation Time: 15.20 CET
Link: <https://bit.ly/3pLfWHx>

Redeye Life Science Day 2020

Date: November 26, 2020
Presentation Time: 16.30 CET
Link: <https://bit.ly/2HkohAH>

Aktiespararna Stora Aktiedagen Stockholm 2020

Date: December 2, 2020
Presentation Time: 11.00 CET
Link: <https://bit.ly/3kQN4tL>

FOR MORE INFORMATION, PLEASE CONTACT:

Sven Rohmann, CEO
Telephone: +46 8 732 8400
E-mail: info@immunicum.com

INVESTOR RELATIONS

Jonas Rodny and Carolin Wiken
Paues Åberg Communications
Telephone: +46 190 90 51
E-mail: ir@immunicum.com

MEDIA RELATIONS

Joanne Tudorica and Sophia Hergenhan, Ph.D.
Trophic Communications
Telephone: +49 171 351 2733
E-mail: ir@immunicum.com

ABOUT IMMUNICUM AB (PUBL)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The Company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving

towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com